Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 4,126 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Monday, September 28th, Marshall Urist sold 4,126 shares of Royalty Pharma stock. The shares were sold at an average price of $57.88, for a total value of $238,812.88.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded down $0.50 during trading on Monday, reaching $56.66. 3,958,012 shares of the company’s stock were exchanged, compared to its average volume of 3,439,495. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. Royalty Pharma PLC has a 1-year low of $35.23 and a 1-year high of $64.38. The company has a market cap of $32.58 billion, a P/E ratio of 39.08, a PEG ratio of 1.35 and a beta of 0.42. The firm’s 50-day moving average price is $59.52 and its 200 day moving average price is $54.96.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The business had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. As a group, research analysts anticipate that Royalty Pharma PLC will post 5.32 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were paid a $0.2350 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Friday, August 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 64.83%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $65.00 target price on shares of Royalty Pharma in a research note on Thursday, August 6th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. TD Cowen increased their price target on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Finally, Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, September 14th. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and an average price target of $61.29.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Ridgewood Investments LLC acquired a new stake in Royalty Pharma during the 3rd quarter worth approximately $208,000. Eastern Bank increased its position in Royalty Pharma by 2.0% in the 3rd quarter. Eastern Bank now owns 708,768 shares of the biopharmaceutical company’s stock valued at $41,364,000 after acquiring an additional 13,843 shares during the period. Sequoia Financial Advisors LLC increased its position in Royalty Pharma by 11.8% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,513 shares of the biopharmaceutical company’s stock valued at $982,000 after acquiring an additional 1,843 shares during the period. Tidal Investments LLC raised its stake in shares of Royalty Pharma by 298.6% during the second quarter. Tidal Investments LLC now owns 118,323 shares of the biopharmaceutical company’s stock valued at $6,634,000 after acquiring an additional 88,642 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Royalty Pharma during the second quarter valued at $1,278,000. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.